ALIMERA SCIENCES INC
alimerasciences.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2024 10-Q, filed Aug 7, 2024. Its latest SEC filing is a SC 13G/A from Nov 13, 2024.
10-Q for Q2 FY2024, filed Aug 7, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Sells ILUVIEN and YUTIQ, prescription implants for diabetic macular edema and chronic non-infectious inflammation in the back of the eye, to pharmaceutical distributors and healthcare providers.
10-K for FY2023, filed Mar 8, 2024We are a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal…View ↗
At Alimera, we internally developed and commercialized ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg, in the U.S. and…View ↗
Both ILUVIEN and YUTIQ treat patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide (“FAc”) in the eye…View ↗
Our revenues for the fiscal years ended December 31, 2023 and 2022 were $56.7 million and $34.2 million, respectively, from the U.S. and…View ↗
How Did They Make Money?
Pharmaceutical distributors and healthcare providers buy the implants; Alimera gets paid for product sales when the goods are delivered to the customer.
10-K for FY2023, filed Mar 8, 2024
-
10-K for FY2023, filed Mar 8, 2024
FY2023 revenue by reportable segment ↗
$80.8M
-
10-K for FY2023, filed Mar 8, 2024
$80.8M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
U.S.
Sold outright
10-K for FY2023, filed Mar 8, 2024 |
70%
FY2020: 49%
|
U.S., FY2023
$56.7M Sources
|
Sold outright |
|
International
Sold outright
10-K for FY2023, filed Mar 8, 2024 |
30%
FY2020: 51%
|
International, FY2023
$24M Sources
|
Sold outright |
Who Were Their Customers?
In the U.S., two large pharmaceutical distributors stock the products and sell them to physician offices, pharmacies and hospitals. Internationally, Alimera sells directly to hospitals, clinics and pharmacies in some countries and through partnering distributors in others.
10-K for FY2023, filed Mar 8, 2024Our revenues for the fiscal years ended December 31, 2023 and 2022 were $56.7 million and $34.2 million, respectively, from the U.S. and…View ↗
10-K for FY2023, filed Mar 8, 2024
For the years ended December 31, 2023 and 2022, there were three customers within the U.S. segment. Two of these customers, which are large…View ↗
Did Revenues Turn Into Profits?
No. It lost $20.1M in FY2023.
10-K for FY2023, filed Mar 8, 2024
−$1.9MView ↗
10-K for FY2023, filed Mar 8, 2024
−$20.1MView ↗
10-K for FY2023, filed Mar 8, 2024
−$14.5MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2024, filed Aug 7, 2024
−$3.3MView ↗
- ▼ −67% (Loss)
- vs −$10M in Q2 FY2023
10-Q for Q2 FY2024, filed Aug 7, 2024
Open tableView ↗
-
Sep 16, 2024
Alimera completed its merger
Each share of common stock was converted into cash consideration and a contingent value right.
Sources
8-K, filed Sep 16, 2024
In connection with the completion of the Merger, on the Closing Date, Parent, on behalf of the Company, repaid in full all indebtedness…View ↗
-
Sep 10, 2024
Alimera sued ANI to compel the merger closing
It asked a Delaware court to require ANI to complete the merger agreement.
Sources
8-K, filed Sep 10, 2024
Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger AgreementView ↗
-
Jun 24, 2024
ANI agreed to acquire Alimera
The deal offered $5.50 per share in cash plus a contingent value right.
Sources
8-K, filed Jun 24, 2024
Princeton, NJ and Atlanta, GA, June 24, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) and…View ↗
Grew. Revenue grew 50% in 4 years, from $53.9M in FY2019 to $80.8M in FY2023, about 11% a year.
Added YUTIQ
The older report says ILUVIEN was Alimera’s only commercial product; the latest report also describes YUTIQ and its commercialization rights.
10-K for FY2020, filed Mar 5, 2021 10-K for FY2023, filed Mar 8, 2024Our only commercial product is ILUVIEN®, an intravitreal implant that treats patients by delivering a continuous microdose of the…View ↗
Who Did They Compete With?
Competes with Regeneron, Bayer, Genentech, Roche, Novartis, Sandoz, Samsung Bioepsis, Biogen, Allergan, AbbVie, and Bausch & Lomb
10-K for FY2023, filed Mar 8, 2024Eylea© (aflibercept) 4 mg and Eylea® HD (aflibercept) 8 mg, marketed by Regeneron in the U.S. and by Bayer in the EEA, are VEGF…View ↗
Loading...
